EP4522143C0 - Behandlung von schmerzen im zusammenhang mit zentraler sensibilisierung - Google Patents

Behandlung von schmerzen im zusammenhang mit zentraler sensibilisierung

Info

Publication number
EP4522143C0
EP4522143C0 EP23837005.0A EP23837005A EP4522143C0 EP 4522143 C0 EP4522143 C0 EP 4522143C0 EP 23837005 A EP23837005 A EP 23837005A EP 4522143 C0 EP4522143 C0 EP 4522143C0
Authority
EP
European Patent Office
Prior art keywords
treatment
pain associated
central sensitization
sensitization
central
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP23837005.0A
Other languages
English (en)
French (fr)
Other versions
EP4522143A1 (de
EP4522143B1 (de
Inventor
Basil Rigas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicon Pharmaceuticals Inc
Original Assignee
Medicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicon Pharmaceuticals Inc filed Critical Medicon Pharmaceuticals Inc
Priority to MA70825A priority Critical patent/MA70825B1/fr
Priority to EP25186722.2A priority patent/EP4603145A3/de
Priority to RS20250746A priority patent/RS67089B1/sr
Priority to SM20250296T priority patent/SMT202500296T1/it
Priority to HRP20251034TT priority patent/HRP20251034T1/hr
Publication of EP4522143A1 publication Critical patent/EP4522143A1/de
Application granted granted Critical
Publication of EP4522143C0 publication Critical patent/EP4522143C0/de
Publication of EP4522143B1 publication Critical patent/EP4522143B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP23837005.0A 2022-11-23 2023-11-21 Behandlung von schmerzen im zusammenhang mit zentraler sensibilisierung Active EP4522143B1 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MA70825A MA70825B1 (fr) 2022-11-23 2023-11-21 Traitement de douleur associée à la sensibilisation centrale
EP25186722.2A EP4603145A3 (de) 2022-11-23 2023-11-21 Behandlung von schmerzen im zusammenhang mit zentraler sensibilisierung
RS20250746A RS67089B1 (sr) 2022-11-23 2023-11-21 Lečenje bola povezanog sa centralnom senzibilizacijom
SM20250296T SMT202500296T1 (it) 2022-11-23 2023-11-21 Trattamento di dolore associato a sensibilizzazione centrale
HRP20251034TT HRP20251034T1 (hr) 2022-11-23 2023-11-21 Liječenje boli povezane sa središnjom senzibilizacijom

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202263384793P 2022-11-23 2022-11-23
US202263384792P 2022-11-23 2022-11-23
US202263384795P 2022-11-23 2022-11-23
US202263384794P 2022-11-23 2022-11-23
US202263384790P 2022-11-23 2022-11-23
US202263384796P 2022-11-23 2022-11-23
US202363483353P 2023-02-06 2023-02-06
PCT/US2023/080646 WO2024112725A1 (en) 2022-11-23 2023-11-21 Treating pain associated with central sensitization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP25186722.2A Division EP4603145A3 (de) 2022-11-23 2023-11-21 Behandlung von schmerzen im zusammenhang mit zentraler sensibilisierung

Publications (3)

Publication Number Publication Date
EP4522143A1 EP4522143A1 (de) 2025-03-19
EP4522143C0 true EP4522143C0 (de) 2025-07-02
EP4522143B1 EP4522143B1 (de) 2025-07-02

Family

ID=89378489

Family Applications (2)

Application Number Title Priority Date Filing Date
EP25186722.2A Pending EP4603145A3 (de) 2022-11-23 2023-11-21 Behandlung von schmerzen im zusammenhang mit zentraler sensibilisierung
EP23837005.0A Active EP4522143B1 (de) 2022-11-23 2023-11-21 Behandlung von schmerzen im zusammenhang mit zentraler sensibilisierung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP25186722.2A Pending EP4603145A3 (de) 2022-11-23 2023-11-21 Behandlung von schmerzen im zusammenhang mit zentraler sensibilisierung

Country Status (16)

Country Link
US (1) US20250345350A1 (de)
EP (2) EP4603145A3 (de)
JP (1) JP2025541617A (de)
KR (1) KR20250123139A (de)
CN (1) CN120569194A (de)
AU (1) AU2023385700A1 (de)
ES (1) ES3036667T3 (de)
HR (1) HRP20251034T1 (de)
HU (1) HUE072771T2 (de)
MA (1) MA70825B1 (de)
MD (1) MD4522143T2 (de)
MX (1) MX2025005914A (de)
PL (1) PL4522143T3 (de)
RS (1) RS67089B1 (de)
SM (1) SMT202500296T1 (de)
WO (2) WO2024112725A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025111078A1 (en) 2023-11-21 2025-05-30 Medicon Pharmaceuticals, Inc. Oral administration of compounds for treating pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060253100A1 (en) 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
ITMI20051107A1 (it) * 2005-06-14 2005-09-13 Ctg Pharma S R L Metodo per il trattamento del cancro
CN101820755B (zh) 2007-08-10 2013-05-15 巴赛尔·雷盖斯 抗炎化合物及其应用
US20130225529A1 (en) 2012-02-27 2013-08-29 Basil Rigas Phospho-ester derivatives and uses thereof
KR20150085509A (ko) 2012-09-21 2015-07-23 바질 리가스 염증-관련 장애, 통증 및 열, 피부 장애, 암 및 이의 전암성 질환의 치료용 조성물
EP3226972A4 (de) * 2014-12-01 2018-08-08 Achelios Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung von migräne und leiden in zusammenhang mit schmerzen
US20200246359A1 (en) 2017-09-28 2020-08-06 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
ES2952672T3 (es) 2021-05-24 2023-11-03 Medicon Pharmaceuticals Inc Tratamiento del dolor neuropático asociado a la neuropatía periférica inducida por la quimioterapia
ES2961829T3 (es) 2021-05-24 2024-03-14 Medicon Pharmaceuticals Inc Tratamiento del dolor asociado a la neuropatía diabética periférica

Also Published As

Publication number Publication date
SMT202500296T1 (it) 2025-09-12
AU2023385700A1 (en) 2025-07-10
KR20250123139A (ko) 2025-08-14
MA70825B1 (fr) 2025-12-31
EP4603145A2 (de) 2025-08-20
WO2024112727A1 (en) 2024-05-30
JP2025541617A (ja) 2025-12-22
WO2024112725A1 (en) 2024-05-30
ES3036667T3 (en) 2025-09-23
PL4522143T3 (pl) 2025-10-13
MD4522143T2 (ro) 2025-11-30
RS67089B1 (sr) 2025-09-30
EP4603145A3 (de) 2025-11-19
CN120569194A (zh) 2025-08-29
EP4522143A1 (de) 2025-03-19
HUE072771T2 (hu) 2025-12-28
MX2025005914A (es) 2025-09-02
HRP20251034T1 (hr) 2025-10-24
EP4522143B1 (de) 2025-07-02
US20250345350A1 (en) 2025-11-13

Similar Documents

Publication Publication Date Title
EP4493064A4 (de) Behandlung von depressionen
EP4373480A4 (de) Behandlung von depression
EP4493539A4 (de) Behandlung von hautneurofibromen mit mirdametinib
EP4346844A4 (de) Behandlung von komplementvermittelten erkrankungen
EP4114466C0 (de) Behandlung von schmerzen und gefässverengung
EP4352231A4 (de) Behandlung von angptl4-bedingten erkrankungen
EP4255458A4 (de) Behandlung von danon-krankheit
EP4188375A4 (de) Behandlung von migräne
EP4466018A4 (de) Behandlung von autoimmun-enzephalitis mit sativalizumab
EP4463157C0 (de) Behandlung von gm2-gangliosidose
EP4441225A4 (de) Behandlung von neurologischen erkrankungen mit modulatoren von unc13a-gentranskripten
EP4514347A4 (de) Behandlung von neurologischen erkrankungen
EP4413032A4 (de) Behandlung von mastzellenbedingten erkrankungen
EP4216952A4 (de) Behandlung von kognitiven störungen mit pyrrolopyridinanilinverbindungen
EP4406538A4 (de) Behandlung von krebspatienten mit kras-mutationen
EP4251753A4 (de) Behandlung von sos2-bedingten erkrankungen und störungen
EP4392413A4 (de) Behandlung von neuroinflammatorischen erkrankungen
EP4211162A4 (de) Behandlung von morbus parkinson
EP4149453A4 (de) Kombinationsbehandlung von lebererkrankungen
EP4238567A4 (de) Neuartige behandlung und prävention von erkrankungen im zusammenhang mit sarkopenie
EP4508207A4 (de) Behandlung von arginase-1-mangel
EP4404953A4 (de) Mrna-regulon-therapie zur behandlung von erkrankungen mit haploinsuffizienz
EP4416176A4 (de) Behandlung von ige-vermittelten erkrankungen
EP4301356A4 (de) Behandlung von brustkrebs mit amcenestratant und palbociclib
EP4355430A4 (de) Behandlung von mst1r-bedingten erkrankungen und störungen

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20251034T

Country of ref document: HR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20241211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: TN

Ref legal event code: VAGR

Ref document number: TN/P/2025/0247

Country of ref document: TN

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602023004568

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20250724

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20250731

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 3036667

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20250923

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20250814

Year of fee payment: 3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HR

Payment date: 20250924

Year of fee payment: 3

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40123373

Country of ref document: HK

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20250909

Year of fee payment: 3

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20251034

Country of ref document: HR

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 47004

Country of ref document: SK

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20250401836

Country of ref document: GR

Effective date: 20251009

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20250925

Year of fee payment: 3

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 3

Effective date: 20251008

REG Reference to a national code

Ref country code: MD

Ref legal event code: VAGR

Ref document number: 4522143

Country of ref document: MD

Date of ref document: 20251130

Kind code of ref document: T2

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20251034

Country of ref document: HR

Payment date: 20250924

Year of fee payment: 3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20251105

Year of fee payment: 3

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E072771

Country of ref document: HU

REG Reference to a national code

Ref country code: MA

Ref legal event code: VAGR

Ref document number: 70825

Country of ref document: MA

Kind code of ref document: B1

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20251113

Year of fee payment: 3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20251113

Year of fee payment: 3

Ref country code: MC

Payment date: 20251028

Year of fee payment: 3

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MD

Payment date: 20251003

Year of fee payment: 3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20251119

Year of fee payment: 3

Ref country code: AL

Payment date: 20251113

Year of fee payment: 3

Ref country code: GR

Payment date: 20251014

Year of fee payment: 3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ME

Payment date: 20250919

Year of fee payment: 3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20251007

Year of fee payment: 3

Ref country code: CZ

Payment date: 20251110

Year of fee payment: 3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20250901

Year of fee payment: 3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20251013

Year of fee payment: 3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RS

Payment date: 20251110

Year of fee payment: 3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20251211

Year of fee payment: 3

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MA

Payment date: 20251218

Year of fee payment: 3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT